Search

Your search keyword '"Schlicker A."' showing total 571 results

Search Constraints

Start Over You searched for: Author "Schlicker A." Remove constraint Author: "Schlicker A." Database Unpaywall Remove constraint Database: Unpaywall
571 results on '"Schlicker A."'

Search Results

1. Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling

2. A multidimensional atlas of human glioblastoma-like organoids reveals highly coordinated molecular networks and effective drugs

4. Game of Roster – GamOR

5. p53 deficient breast cancer cells reprogram preadipocytes toward tumor-protective immunomodulatory cells

6. OA-652 Safety and tolerability of favipiravir for the treatment of Lassa fever: a randomized controlled open label phase II clinical trial

7. Sex-specific Expression of Estradiol Derivatives, Hydropersulfides and Ether Lipids Regulates Ferroptosis Sensitivity of Kidney Tubules

14. Formate promotes invasion and metastasis in reliance on lipid metabolism

15. Novel YAP1/TAZ pathway inhibitors identified through phenotypic screening with potent anti-tumor activity via blockade of GGTase-I / Rho-GTPase signaling

16. 13C-SpaceM: Spatial single-cell isotope tracing reveals heterogeneity ofde novofatty acid synthesis in cancer

19. LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma

24. Predicting heterogeneous treatment effects of an Internet-based depression intervention for patients with chronic back pain: Secondary analysis of two randomized controlled trials

25. USP28 controls SREBP2 and the mevalonate pathway to drive tumour growth in squamous cancer

26. Abstract 3571: The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models

27. Abstract 234: ITCC-P4: Genomic profiling and analyses of pediatric patient tumor and patient-derived xenograft (PDX) models for high throughput in vivo testing

29. Data from First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

30. Supplemental Tables S1-3 from Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance

33. Data from Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance

34. Supplementary Methods from Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance

35. Supplementary Figures from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

36. Supplementary Methods from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

37. Data from Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance

43. Supplementary Data from First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

46. Data from First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

47. Figures S1-S5 from Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance

49. Supplementary Data from First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors

50. Supplementary Tables from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

Catalog

Books, media, physical & digital resources